1、Pharma R&D Annual Review 2022 Supplement:New Active Substances Launched During 2021Discover more at: Paper2IntroductionFollowing on from our review of trends in the current pharmaceutical R&D pipeline (download the report for free),this supplement takes a look at the industrys success stories of 202

2、1 the drugs which were launched onto the market for the first time during the year.Our survey focuses exclusively on new active substances(NASs):new chemical or biological entities where the active ingredient had received no prior approval for human use.This would also include vaccines with novel an

3、tigenic components.As such,this list represents a subset of all the first launches which Pharmaprojects reported during 2021,and excludes an additional 75 first drug launches of reformulated or non-NAS moieties,biosimilars,and imaging agents.So,to continue with our travel-based theme this year,these

4、 are drugs which remembered their passports,tickets,and vaccine certificates,boarded the plane for their flight through clinical development,touched down safely,and have now successfully completed their journey and arrived at their chosen destination.Travel was one of the pleasures in life which we

5、had previously taken for granted that was most affected by the COVID-19 pandemic over the past two years.Whereas usually,one could board a plane at the drop of a hat and be in foreign climes by teatime,for much of 2020 and 2021,international travel was completely out of the question.Indeed,during lo

6、ckdowns,in the UK at least,we were only permitted to leave our homes for essential food buying or our once-daily permitted bout of exercise.As our worlds essentially shrank to the size of our living rooms,somehow,drugs continued on their journeys through research and development.In the first part of